Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary Hyperlipidemia | Phase 2 | CN | 08 Nov 2021 | |
Hypercholesterolemia | Phase 2 | CN | - | |
Heterozygous familial hypercholesterolemia | Preclinical | CN | 12 Feb 2019 | |
Hyperlipoproteinemia Type II | Preclinical | CN | 12 Feb 2019 |